Cases of completed suicides and attempted suicides with the insomnia drug Belsomra have raised concerns with the Institute for Safe Medication Practices (ISMP) in its QuarterWatch review. The organization monitors Food and Drug Administration (FDA) MedWatch adverse event reports each quarter. Belsomra was approved by the FDA in 2014. It contains the active ingredient suvorexant, which works by blocking two newly discovered neurotransmitters called orexins. Neurons that emit orexin send wakefulness signals to the complex neural circuits that regulate sleep and waking cycles. Belsomra was developed under the idea that blocking these wakeful signals at night would help people sleep. During ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.